TaiRx (TPEX:6580) - Share price, News & Analysis

6580 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

6580 Stock Overview

TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases.

Risk Analysis

Earnings have declined by 3.6% per year over past 5 years

Makes less than USD$1m in revenue (NT$5M)

TaiRx Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TaiRx
Historical stock prices
Current Share Price	NT$35.10
52 Week High	NT$89.50
52 Week Low	NT$26.25
Beta	0.66
1 Month Change	-10.00%
3 Month Change	-11.25%
1 Year Change	24.91%
3 Year Change	49.25%
5 Year Change	n/a
Change since IPO	-38.46%

Recent News & Updates

Mar 24

Companies Like TaiRx (GTSM:6580) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Dec 09

We Think TaiRx (GTSM:6580) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	6580	TW Biotechs	TW Market
7D	-5.6%	-2.8%	-0.8%
1Y	24.9%	6.7%	4.2%

Return vs Industry: 6580 exceeded the TW Biotechs industry which returned 6.7% over the past year.

Return vs Market: 6580 exceeded the TW Market which returned 4.2% over the past year.

Price Volatility

Is 6580's price volatile compared to industry and market?
6580 volatility
6580 Average Weekly Movement	5.9%
Biotechs Industry Average Movement	5.3%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6580 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6580's weekly volatility has decreased from 13% to 6% over the past year.

About the Company

Founded	Employees	CEO	Website
2011	n/a	Chien Du-Shieng	https://www.trx.com.tw

TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis.

TaiRx Fundamentals Summary

How do TaiRx's earnings and revenue compare to its market cap?
6580 fundamental statistics
Market Cap	NT$3.16b
Earnings (TTM)	-NT$125.61m
Revenue (TTM)	NT$5.14m

615.7x

P/S Ratio

-25.2x

P/E Ratio

Is 6580 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
6580 income statement (TTM)
Revenue	NT$5.14m
Cost of Revenue	NT$2.69m
Gross Profit	NT$2.45m
Other Expenses	NT$128.06m
Earnings	-NT$125.61m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.39
Gross Margin	47.62%
Net Profit Margin	-2,443.36%
Debt/Equity Ratio	0%

How did 6580 perform over the long term?

See historical performance and comparison

Valuation

Is TaiRx undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.69x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6580's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6580's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6580 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6580 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6580's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6580 is overvalued based on its PB Ratio (4.7x) compared to the TW Biotechs industry average (3.9x).

Future Growth

How is TaiRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

124.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has TaiRx performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-3.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6580 is currently unprofitable.

Growing Profit Margin: 6580 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6580 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare 6580's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6580 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 6580 has a negative Return on Equity (-18.86%), as it is currently unprofitable.

Financial Health

How is TaiRx's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6580's short term assets (NT$571.4M) exceed its short term liabilities (NT$24.8M).

Long Term Liabilities: 6580's short term assets (NT$571.4M) exceed its long term liabilities (NT$5.9M).

Debt to Equity History and Analysis

Debt Level: 6580 is debt free.

Reducing Debt: 6580 has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6580 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6580 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 2% each year

Dividend

What is TaiRx current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6580's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6580's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6580's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6580's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6580 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Chien Du-Shieng

no data

Tenure

Dr. Chien Du-Shieng, Ph.D. is the Scientific Director of Efficient Pharma Management Corp. Dr. Du-Shieng served as Chief Executive Officer and President of SunTen Phytotech Co. Ltd. He served several manag...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/17 00:00
End of Day Share Price	2022/05/17 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31